We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Palleon Pharmaceuticals has raised $100m in a Series B financing round to develop drugs targeting glycan-mediated immune regulation to treat cancer and inflammatory diseases.